In multiple trials, baricitinib has proved promising for treating RA. Also, the FDA is requiring drug-interaction studies for sodium polystyrene sulfonate…
Search results for: adalimumab
German Registry Evaluates Systemic Psoriasis Treatments
The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…
Rectosigmoidoscopy vs. Colonoscopy for Assessing Ulcerative Colitis Activity
NEW YORK (Reuters Health)—In most cases, rectosigmoidoscopy and colonoscopy assessments of disease activity in ulcerative colitis yield the same results, researchers report. “In clinical practice, rectosigmoidoscopy is enough to assess endoscopic activity and endoscopic healing,” Dr. Jean-Frédéric Colombel from Icahn School of Medicine at Mount Sinai, N.Y., told Reuters Health by email. Dr. Colombel and…
Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events
The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…
Patients with Psoriasis, Psoriatic Arthritis at Increased Risk of Migraine
NEW YORK (Reuters Health)—Psoriasis and psoriatic arthritis are associated with an increased risk of migraine, according to new research from Denmark. “The main finding of our study was a psoriasis severity-dependent increased risk of new-onset migraine, and patients with severe skin psoriasis and psoriatic arthritis appeared to have the highest risk,” Dr. Alexander Egeberg from…
Guselkumab Studied to Treat RA, Plaque Psoriasis
Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…
EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
ROME, Italy—When it comes to thinking about disease modification—a main goal in the treatment of axial spondyloarthritis (axial SpA) and other inflammatory diseases—it’s time to reconsider the concept, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). The traditional way of assessing disease modification, inhibiting radiographic progression, is…
EULAR 2015: Anti-Inflammatory Drugs with Dual Targets
Antibody-like molecules that can bind to more than one target—with the goal of having a more powerful effect than if those targets were treated separately in a combination of therapies—could become part of treatment regimens in rheumatic diseases over the next several years, an expert said here in a session at EULAR 2015, the annual…
Early, Aggressive Therapy for RA May Result in Cost Savings Long Term
By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…
EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics
ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 36
- Next Page »